Immune System Diseases Completed Phase 4 Trials for Mesalazine (DB00244)

Also known as: Immune System Disease

IndicationStatusPhase
DBCOND0029769 (Immune System Diseases)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01090102Mesalamine to Reduce T Cell Activation in HIV InfectionTreatment